Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
  2. >
  3. News
  4. >
  5. Everlywell Launches Eva Engage, Boosting Member Engagement by 50%

Everlywell Launches Eva Engage, Boosting Member Engagement by 50%

Written by Emily J. Thompson, Senior Investment Analyst
stocks logo
EVER.O-1.44%
Source: Businesswire
Updated: 45 minutes ago
0mins
Intellectia AI SwingMax
Intellectia AI SwingMax
Source: Businesswire
  • Personalized Interaction Boost: Everlywell's deployment of Eva Engage's AI Voice Agent led to 60,000 member calls, driving nearly a 50% increase in member engagement, indicating that personalized health outreach significantly enhances user activity and involvement.
  • Multilingual Support Advantage: Engagement rates among Spanish-preferred members were over double that of non-Spanish-preferred members, with order completion rates tripling, demonstrating the critical value of multilingual personalized outreach at scale in health management.
  • High Resolution Rate: Eva Engage achieved a nearly 70% successful resolution rate, aligning with the industry benchmark typically met by trained human teams, showcasing the efficiency and reliability of AI in healthcare support.
  • Advancing Proactive Care: By precisely reaching members, Eva Engage accelerates Everlywell's mission to promote personalized care, reinforcing its role as a trusted partner in the future of healthcare.
stocks logo
EVER.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
no data image
No Data
Powered By
Intellectia
Analyst Views on EVER
Wall Street analysts forecast EVER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVER is 33.25 USD with a low forecast of 30.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast EVER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVER is 33.25 USD with a low forecast of 30.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 27.800
sliders
Low
30.00
Averages
33.25
High
40.00
Current: 27.800
sliders
Low
30.00
Averages
33.25
High
40.00
Raymond James
Strong Buy -> Outperform
downgrade
$35 -> $30
2025-09-22
Reason
Raymond James
Price Target
$35 -> $30
2025-09-22
downgrade
Strong Buy -> Outperform
Reason
Raymond James downgraded EverQuote to Outperform from Strong Buy with a price target of $30, down from $35. The firm sees the company's revenue growth decelerating year-over-year in Q3 and beyond as its prior year period comps normalize. EverQuote's revenue growth could moderate to a high single-digit rate by fiscal 2027, which is below management's target, the analyst tells investors in a research note.
Canaccord Genuity
Michael Graham
Strong Buy
Maintains
$35 → $30
2025-02-24
Reason
Canaccord Genuity
Michael Graham
Price Target
$35 → $30
2025-02-24
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on EverQuote to $30 from $35 and keeps a Buy rating on the shares. The firm previewed its quarter and expects EverQuote to report strong Q4 results, reflecting healthy carrier profitability and a broadening of the recovery in auto insurance customer acquisition spend.
JP Morgan
Cory Carpenter
Buy
Maintains
$28 → $25
2025-01-10
Reason
JP Morgan
Cory Carpenter
Price Target
$28 → $25
2025-01-10
Maintains
Buy
Reason
Raymond James
Aaron Kessler
Buy
to
Strong Buy
Upgrades
$35
2024-12-26
Reason
Raymond James
Aaron Kessler
Price Target
$35
2024-12-26
Upgrades
Buy
to
Strong Buy
Reason
Raymond James analyst Gregory Peters upgraded EverQuote to Strong Buy from Outperform with a $35 price target.
See All Ratings
Financial AI Agent
Financial AI Agent
About EVER
EverQuote, Inc. operates an online marketplace for consumers shopping for auto and home and renters insurance quotes. The Company operates a marketplace connecting insurance providers to a large volume of high-intent, pre-validated consumer referrals that match the insurers' specific underwriting and profitability requirements. Its marketplace enables consumers to choose to visit an insurance provider's Website to purchase a policy or engage with a carrier or agent by phone or submit their data to insurance providers to receive quotes. Its technology platform combines internally developed, third-party and open-source software. Its Websites and supporting services, as well as its development and test environments, are hosted across industry-standard cloud providers, such as Amazon Web Services and Google Cloud Platform. The Company's insurance provider customers include insurance carriers and third-party insurance agents.

About the author

Emily J. Thompson
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Top News

SpaceX Targets $800 Billion Valuation in Secondary Sale

06 Dec 25
news image

U.S. Consumer Sentiment Slightly Improves in December

06 Dec 25
news image

U.S. Consumer Spending Slows in September

06 Dec 25
news image

Netflix Acquires Warner Bros. Assets in $72B Deal

05 Dec 25
news image

Related Articles

Paramount Skydance Launches $108.4 Billion Hostile Bid for Warner Bros Discovery

00:11 AM
news image

Trump's Economic Management Trust Leads by 10 Points Over Democrats

12-08
news image

Sigh Up to Get Intellectia Insights

arrow icon

How did Eva Engage improve Everlywell's member engagement by nearly 50%?

arrow icon

What factors contributed to Eva Engage's high resolution rate of 70%?

arrow icon

Will Everlywell's use of Eva Engage lead to further engagement growth?

arrow icon

Can Marsh & McLennan sustain its growth through continued acquisitions?

arrow icon

What does the multilingual support success reveal about healthcare outreach strategies?

People Also Watch

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free